Outsourcing: Analysis and developments of contract service providers to the pharmaceutical and biotechnology industries - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Outsourcing
Contract manufacturing organizations (CMOs) and contract research organizations (CROs). Global sourcing of pharma ingredients and services. Trends and challenges for the biopharmaceutical and pharmaceutical industries.

Fast Locator Index 2013-2014: API Production Technologies

August 1, 2013

Fast Locator Index 2013-2014: API Production Technologies

Strengthening the Supply Chain for Pharmaceutical Ingredients

July 2, 2013

Pharmaceutical Technology

The US and EU move forward with measures to fortify the pharmaceutical supply chain.

Q&A with Claudia Roth, President, Vetter Development Service, USA

July 2, 2013
Pharmaceutical Technology

Claudia Roth, President of Vetter Development Service USA, discusses trends in single-use technology for clinical manufacturing.

What Happened to Outsourcing in Asia?

July 2, 2013

Pharmaceutical Technology

The industry may not be ready for India and China as regulatory issues emerge.

Gauging Investment in High-Potency Manufacturing

July 2, 2013

Pharmaceutical Technology

Contract service providers expand capabilities in API and finished product manufacturing to meet demand for high-potency drugs.

Drug Approval Trends Don't Extend to CMOs

June 2, 2013

Pharmaceutical Technology

Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.

Outsourcing's Modest Role as a Cost-Containment Strategy

May 2, 2013

Pharmaceutical Technology

Outsourcing is weighing in more as a tactic for cost-cutting, but it is still not the primary weapon.

Strategic Partnering for Manufacturing

April 2, 2013

Pharmaceutical Technology

Eisai and Biogen Idec pursue an innovative approach to capacity management.

Navigating the Global Manufacturing Supply Chain

March 2, 2013

Pharmaceutical Technology

As the strategic value of emerging markets increase, pharmaceutical companies increase their R&D and manufacturing investments.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
Click here